Eli Lilly, Ascidian Sign $1.9 Billion Kidney-Disease Treatment Deal
Eli Lilly signed a collaboration and licensing agreement worth up to $1.9 billion with Ascidian Therapeutics to research and develop kidney-disease treatments.
Connecting Global Economies
Flash News
David Archuleta Details Engagements to 3 Women Before Coming Out
Aryna Sabalenka undone by the wind at French Open again as Diana Shnaider seizes her moment
Eli Lilly, Ascidian Sign $1.9 Billion Kidney-Disease Treatment Deal
KKR, Blackstone and Ares shares tumble on private equity jitters
Teddi Mellencamp Shares Update on Cancer Treatments
Brewers’ Kyle Harrison, after dominating Giants, leaves no doubt he’s in a better place
ADP jobs report May 2026: Payrolls increase by 122,000
Pink’s Advice to Daughter Willow Hart on 15th Birthday
NBA’s ‘Script F’ Finals logo, 40 years after its debut, still means a team has made it big
Baidu Sees AI, Chip Business Driving Healthy Revenue Growth
Wednesday, June 03, 2026